Do ashwagandha have side effects?
People do not usually ask about ashwagandha because they want a scare story. They ask because a friend swore it calmed them down, a bottle promised stress relief, and then a search result mentioned liver injury, thyroid swings, or stomach pain. The honest answer is yes — ashwagandha can have side effects — and the more useful answer is that most of those effects, in human trials of standardized root extracts such as KSM-66, are mild, uncommon, and dose-dependent, while a smaller set of people should not take it at all.
Most ashwagandha side effects reported in clinical trials are mild. The risk changes when the extract is unstandardized, the dose is high, or the person already has thyroid, liver, or pregnancy-related concerns.
Ashwagandha (Withania somnifera) is an adaptogenic root used for centuries in Ayurveda. Modern shoppers meet it as capsules, gummies, and powders marketed for stress, sleep, and recovery. That popularity is why safety questions now matter more than folklore. The American Psychological Association has documented persistently high adult stress for years, and ashwagandha is one of the few botanicals with multiple randomized, placebo-controlled human trials behind a specific extract rather than a vague herb name.
Side-effect conversations go wrong when every ashwagandha product is treated as identical. A tea, a whole-plant powder, a leaf-containing extract, and a root-only extract standardized to withanolides are not the same intervention. Clinical safety data cluster around branded root extracts. Case reports of more serious harm often involve products whose composition, dose, and contaminants were never verified the way a trial material is verified.
In the landmark 2012 randomized trial of high-concentration full-spectrum ashwagandha root extract (KSM-66), 300 mg twice daily for 60 days reduced perceived stress and lowered serum cortisol by 27.9% versus 7.9% on placebo, with adverse events described as mild and comparable between groups. (1)
That is why extract identity matters. KSM-66 is a root-only extract produced with a milk-based green-chemistry process, standardized to at least 5% withanolides, and studied in more than two dozen human trials. Generic labels that simply say "ashwagandha" do not guarantee that chemistry — and they do not inherit that safety file.
This article separates common, usually reversible reactions from rare but documented risks, explains how KSM-66 acts on the stress axis, reviews the human evidence, and outlines who should skip ashwagandha or speak with a clinician first.
What is KSM-66 ashwagandha?
Withania somnifera, commonly called ashwagandha or Indian winter cherry, is classified in Ayurveda as a rasayana — a rejuvenative tonic traditionally used for vitality, recovery, and resilience under strain. The plant belongs to the nightshade family (Solanaceae). The part used in the strongest modern clinical literature is the root, not the leaf.
The primary bioactive compounds are withanolides, a family of steroidal lactones. These molecules appear to influence the hypothalamic-pituitary-adrenal (HPA) axis, GABA-related calming pathways, and selected inflammatory and thyroid markers. Withanolide content is the usual standardization target because raw root powder can vary widely from batch to batch.
KSM-66 is a full-spectrum root extract made without alcohol, using a process that retains the native withanolide profile rather than isolating a single molecule. It is standardized to ≥5% withanolides by HPLC, is root-only, and has been used at 300–600 mg per day in published human trials on stress, sleep, strength, and sexual function. Those manufacturing details are not marketing garnish. They are the reason a safety discussion can cite actual doses and adverse-event tables instead of internet anecdotes.
How KSM-66 ashwagandha works: why side effects show up where they do
Ashwagandha is not a sedative in the pharmaceutical sense, and it is not a stimulant. It is an adaptogen: it appears to nudge a dysregulated stress system back toward a more normal range. That same biology explains both the benefits people want and the side effects a minority notice.
Chronic psychological load keeps the hypothalamus signaling the pituitary gland, which signals the adrenal cortex to keep releasing cortisol. When that loop stays on, people feel wired at night, flattened by afternoon, and unusually reactive to small stressors. Withanolides appear to dampen this HPA overdrive and may also interact with GABAergic signaling, which is why some users feel calmer or sleepier after an evening dose. (2)
When the same pathways are pushed in a sensitive person, the "side effect" is often just the intended pharmacology showing up too strongly: drowsiness, vivid dreams, a heavier-than-expected evening wind-down. Gastrointestinal effects are a separate, more mechanical issue — concentrated botanical extracts can irritate an empty stomach.
A third pathway matters for safety counseling. Ashwagandha has been shown in a small clinical study to raise thyroid hormones in people with subclinical hypothyroidism. (3) That is useful if the thyroid is underactive and medically supervised. It is a problem if someone already has hyperthyroidism or is on thyroid replacement without monitoring.
The net clinical picture at 300–600 mg/day of a standardized root extract is usually this: lower perceived stress, modestly lower cortisol, better sleep continuity for many users, and a low rate of mild adverse events. Serious events are not the typical trial finding. They appear mainly in case reports involving idiosyncratic liver injury, thyroid overstimulation, or use in people who should have been excluded.
Withanolides calm HPA-axis output for most users. The same signaling can cause sleepiness; GI lining irritation explains most early dropouts; rare liver-injury reports sit outside the typical trial safety profile.
What the clinical research shows about side effects
Stress trials: adverse events look like placebo
Chandrasekhar, Kapoor, and Anishetty randomized 64 adults with chronic stress to 300 mg KSM-66 twice daily or placebo for 60 days. Stress scores fell across standard scales, and serum cortisol dropped 27.9% from baseline. Safety monitoring found only mild events and no serious adverse events; laboratory values did not shift in a clinically meaningful way. (1)
Lopresti and colleagues later tested 240 mg/day of a standardized ashwagandha extract for 60 days in stressed adults. Anxiety and morning cortisol improved versus placebo. The extract was described as well tolerated, again without a safety signal that would distinguish it from placebo in a meaningful way. (2)
Dedicated safety study in healthy adults
A 2021 randomized, placebo-controlled safety study in healthy volunteers specifically asked whether ashwagandha root extract disturbed thyroid, liver, hematologic, or vital-sign parameters. Over 8 weeks, researchers reported no significant abnormalities in liver enzymes, thyroid panel, blood counts, or vitals compared with placebo. That paper is one of the cleaner answers to "is this herb quietly toxic at clinical doses?" — in healthy adults, at a studied root-extract dose, the laboratory answer was no. (4)
Sleep studies: sedation is often the point
Langade et al. evaluated 300 mg of ashwagandha root extract twice daily for 10 weeks in adults with insomnia. Sleep onset, sleep efficiency, and sleep quality improved versus placebo. Somnolence in this setting is frequently listed as a side effect and, for people taking the herb at night, as a desired effect. The distinction is timing and context, not a hidden toxicity. (5)
Thyroid data: a real effect, not a rumor
Sharma, Basu, and Singh studied 600 mg/day of ashwagandha root extract for 8 weeks in patients with subclinical hypothyroidism. Serum TSH fell and T3 and T4 rose significantly versus placebo. (3) That is evidence of a genuine endocrine effect. It is also the reason people with known hyperthyroidism, Graves disease, or unstable thyroid replacement should not self-experiment.
Rare liver injury: case reports, not trial tables
A 2023 case series from India and a growing LiverTox file document idiosyncratic ashwagandha-associated liver injury. Presentations have included jaundice, itch, and mixed or cholestatic enzyme patterns, typically weeks to months after starting a product. Most published cases improved after stopping the herb; a minority were more severe. (6) These reports matter. They do not mean typical KSM-66 trial participants developed hepatitis. They mean ashwagandha is not risk-free in every host, every product, and every unregulated dose — and anyone who develops unexplained fatigue, dark urine, pale stools, or yellowing of the skin should stop the supplement and get labs.
A 2020 evidence review of ashwagandha root in human ailments likewise characterized the root as generally safe at studied doses while flagging the usual exclusions: pregnancy, hormone-sensitive conditions, and concomitant use that has not been medically reviewed. (7)
Dosage, form, and what to look for on the label
Across the human clinical trial literature, the effective dose range for KSM-66 ashwagandha is 300–600 mg per day, often given as 300 mg twice daily or 600 mg once daily. Most trials ran for 8–12 weeks, with participants reporting meaningful improvement beginning around 2–4 weeks. Going far above the studied range does not have a matching safety file, and it is one of the easier ways to manufacture a side-effect story.
What to look for on the label:
- Ingredient specifically listed as KSM-66® or Withania somnifera root extract (KSM-66)
- Standardized to ≥5% withanolides
- Root extract only (not leaf or whole-plant)
- Minimum 600 mg per daily serving if the goal is to match the most common clinical dose
- Third-party tested (NSF, Informed Sport, or equivalent)
Avoid products that simply list "ashwagandha" without specifying a standardized extract — these products typically contain trace or highly variable amounts of withanolides and will not replicate the clinical outcomes, or the adverse-event rates, documented in published trials.
Safety profile and side effects
In randomized trials of KSM-66 and closely related root extracts at 240–600 mg/day, ashwagandha has been well tolerated. Serious adverse events have not been a feature of those datasets. When side effects appear, they are usually mild, appear in the first two weeks, and resolve with food, a lower dose, or stopping the product. That is the typical profile — not a guarantee for every person or every untested blend.
Mild side effects reported in a minority of participants include:
- Mild GI upset, nausea, or loose stool if taken on an empty stomach
- Mild sedation or next-morning grogginess (particularly with evening dosing — often considered useful for sleep)
- Rare cases of vivid dreams or headache
- Transient increase in appetite or a heavier, "slowed down" feeling in the first days
Take with food or a small snack to minimize GI sensitivity, especially during the first two weeks. If drowsiness is unwelcome, move the capsule to evening. If drowsiness is the goal, do not stack ashwagandha with alcohol, sedative medications, or other strong calming herbs without medical advice.
Stop and seek care for symptoms that are not mild: yellowing of the eyes or skin, persistent upper-right abdominal pain, very dark urine, unexplained itching, racing heart, marked agitation, or a sudden change in thyroid symptoms. Those are not "adjust the dose" problems.
Who should — and shouldn't — take KSM-66
Ideal candidates
- Healthy adults with persistent perceived stress who want a clinically studied root extract rather than a generic powder
- Adults whose main complaint is "tired but wired" sleep, after medical causes have been considered
- Athletes and high-output professionals already using evidence-based recovery habits who want HPA-axis support at a trial-matched dose
- People who prefer a standardized, third-party-tested capsule over unstandardized teas and bulk powders
Who should consult a physician first?
- Pregnancy and breastfeeding: Traditional texts and modern reviewers advise against ashwagandha in pregnancy because of possible uterine and hormonal effects. Do not self-supplement.
- Hyperthyroidism or unstable thyroid disease: Root extract can raise T3/T4. Combining it with thyroid hormone or taking it in Graves disease is a medical decision, not a wellness experiment.
- Known liver disease or unexplained enzyme elevations: Idiosyncratic injury is rare, but a damaged liver is the wrong place to test an herbal unknown.
- Hormone-sensitive prostate cancer or androgen-related conditions: Some data suggest ashwagandha can influence testosterone and related markers. Get specialist clearance.
- Autoimmune disease on immunosuppressants: Theoretical immune-stimulating effects mean this should be cleared with the prescribing clinician.
- Upcoming surgery or sedative / thyroid/diabetes medication: Additive sleepiness and possible effects on glucose and thyroid labs require a plan to pause or monitor.
- Nightshade allergy: Ashwagandha is a Solanaceae plant. Skip it if you react to that family.
If you want the root extract actually used in human trials — not a mystery powder — start with a labeled KSM-66 dose and treat side effects as data, not as something to push through.
Daily Nutra KSM-66 Ashwagandha 600mg
Better Ingredients | 100% Money Back Guarantee | 10 Years of Ancient Wisdom + Modern Science
Each serving delivers 600mg of clinically studied KSM-66® ashwagandha root extract, standardized to ≥5% withanolides — the exact form and dose used in published human clinical trials on stress, sleep, and recovery. No fillers, no proprietary blends. Just the root extract that works.
Shop KSM-66 Ashwagandha →References
- Chandrasekhar K, Kapoor J, Anishetty S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. PubMed
- Lopresti AL, Smith SJ, Malvi H, Kodgule R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine. PubMed
- Sharma AK, Basu I, Singh S. (2018). Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: A double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine. PubMed
- Verma N, Gupta SK, Tiwari S, Mishra AK. (2021). Safety of ashwagandha root extract: A randomized, placebo-controlled, study in healthy volunteers. Complementary Therapies in Medicine. PubMed
- Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. (2019). Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. Cureus. PubMed
- Philips CA, Valsan A, Theruvath AH, et al. (2023). Ashwagandha-induced liver injury — A case series from India and literature review. Hepatology Communications. PubMed
- Tandon N, Yadav SS. (2020). Safety and clinical effectiveness of Withania somnifera (Linn.) Dunal root in human ailments. Journal of Ethnopharmacology. PubMed
